1023649-51-5

Basic information

• Product Name: 4-Hydrazinyl-2-methylbenzonitrile
• Synonyms: 4-Hydrazinyl-2-methylbenzonitrile
• CAS NO: 1023649-51-5
• Molecular Formula: C₈H₉N₃
• Molecular Weight: 147.17716
• Mol File: 1023649-51-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Hydrazinyl-2-methylbenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydrazinyl-2-methylbenzonitrile(1023649-51-5)
• EPA Substance Registry System: 4-Hydrazinyl-2-methylbenzonitrile(1023649-51-5)

Safety Data

• Hazardous Substances Data: 1023649-51-5(Hazardous Substances Data)

Upstream product

• 147754-12-9 4-fluoro-2-methylbenzonitrile 

Downstream Products

• 1023649-49-1 4-hydrazinyl-2-methylbenzonitrile hydrochloride 
• 1246765-50-3 4-(5-(3,3-difluorocyclobutyl)-3-oxopyrazolidin-1-yl)-2-methylbenzonitrile 
• 1246765-53-6 6-[1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl]-2-methoxynicotinic acid 
• 1246765-54-7 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid 
• 1246765-55-8 (S)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid 
• 1246765-08-1 4-(5-cyclopentyl-3-oxopyrazolidin-1-yl)-2-methylbenzonitrile 
• 1359968-96-9 2-(4-cyano-3-methylphenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinoline-7-carboxylic acid 
• 1359970-21-0 methyl 2-(4-cyano-3-methylphenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinoline-7-carboxylate 

Relevant articles and documents

Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist

The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4, Cy and n are as presented in the description.